Dianthus Therapeutics (NASDAQ:DNTH) Trading 7.8% Higher – What’s Next?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) traded up 7.8% during trading on Monday . The stock traded as high as $27.30 and last traded at $27.09. 142,627 shares were traded during mid-day trading, a decline of 51% from the average session volume of 290,740 shares. The stock had previously closed at $25.12.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. TD Cowen started coverage on Dianthus Therapeutics in a research note on Friday, December 20th. They set a “buy” rating on the stock. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer lifted their price target on shares of Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $46.43.

Dianthus Therapeutics Price Performance

The firm has a 50-day moving average price of $24.61 and a two-hundred day moving average price of $26.59. The company has a market capitalization of $757.09 million, a price-to-earnings ratio of -10.23 and a beta of 1.74.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to the consensus estimate of $1.07 million. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. State Street Corp lifted its stake in Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after acquiring an additional 413,425 shares during the last quarter. Janus Henderson Group PLC raised its holdings in shares of Dianthus Therapeutics by 40.5% in the 3rd quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after purchasing an additional 273,670 shares during the period. Point72 Asset Management L.P. lifted its stake in Dianthus Therapeutics by 151.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock valued at $11,984,000 after purchasing an additional 263,500 shares during the last quarter. Great Point Partners LLC grew its holdings in Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after purchasing an additional 132,929 shares during the period. Finally, Braidwell LP increased its position in Dianthus Therapeutics by 34.6% during the third quarter. Braidwell LP now owns 493,687 shares of the company’s stock worth $13,517,000 after buying an additional 126,836 shares during the last quarter. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.